CTOs on the Move

XyloCor

www.xylocor.com

 
XyloCor Therapeutics is a biopharmaceutical company focused on the development of novel gene therapy for unmet needs in advanced coronary artery disease. In the United States, coronary artery disease is a leading cause of death and disability. The Company`s lead product candidate, XC001, is in clinical development to investigate use for patients with refractory angina for which there are no treatment options. XyloCor also has a secondary product, XC002, in discovery stage, being developed for the treatment of patients with cardiac tissue damage from heart attacks. Co founded by Ronald Crystal, MD, and Todd Rosengart, MD, XyloCor has a licensing ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details
Alexander Gaidamaka
Senior Vice President of Technology, Manufacturing and Quality Profile

Funding

XyloCor raised $17M on 12/06/2018
XyloCor raised $22.6M on 03/22/2021

Similar Companies

Enzo Life Sciences

"Enzo Life Sciences is a wholly owned subsidiary of Enzo Biochem headquartered in Farmingdale, New York. Enzo Biochem is a pioneer in molecular diagnostics, leading the convergence of clinical laboratories, life sciences and therapeutics through the development of unique diagnostic platform technologies that provide numerous advantages over previous standards. A global company, Enzo Biochem utilizes cross-functional teams to develop and deploy products systems and services that meet the ever-changing and rapidly growing needs of healthcare both today and into the future. Underpinning Enzo Biochem’s technologies, platforms and products is a broad and deep intellectual property portfolio, with patent coverage across a number of key enabling technologies. Enzo Life Sciences is a pioneer in labeling and detection technologies from DNA to whole cell across research and diagnostic markets. We are focused on providing cost-effective, relevant and reliable solutions for life science research, drug development, and clinical research. We are organized to lead in the development, production, marketing, and sales of innovative research tools worldwide based on 40 years’ experience in building strong global market recognition and implementing outstanding operational capabilities. Our strong portfolio of proteins, antibodies, peptides, small molecules, labeling probes, dyes and kits provides researchers tools for target identification/validation, high content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis."

RayzeBio

RayzeBio is a biotechnology company focused on improving outcomes for people with cancer by harnessing the power of targeted radioisotopes. With a focus on clinically validated solid tumor targets, RayzeBio is developing novel drug conjugates to deliver potent therapeutic radioisotopes such as Actinium-225, an alpha-emitter. The company is backed by a syndicate of sophisticated healthcare investors and was established in 2020

Solstice Neurosciences

Solstice Neurosciences is a South San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Molecular Express

Molecular Express is a Rancho Dominguez, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Forge Therapeutics Inc

Forge Therapeutics is a biotechnology company developing novel medicines by combining bio-inorganic with medicinal chemistry to target metalloproteins. Forge has developed a fundamentally new approach for the discovery of metalloprotein inhibitors by focusing first on the metal in the enzyme active site.